肌内注射与静脉注射纳洛酮逆转住院患者美沙酮过量:随机对照试验
Intramuscular versus intravenous naloxone for the reversal of methadone overdose in hospitalized patients: a randomized clinical trial
本研究为单中心开放标签随机对照试验(IRCT20120629010133N6),纳入160名临床诊断的美沙酮过量住院患者,随机分配至肌内注射或静脉注射纳洛酮组。
Introduction
The Centers for Disease Control and Prevention have categorized the opioid epidemic into three waves. The initial two waves, spanning from the 1990s to the early 2000s, saw a rise in opioid prescriptions and heroin consumption. During this period, opioid overdose-related mortality increased fourfold between 1990 and 2010, resulting in more than 100 deaths per day1,2. The third wave, which emerged in 2013, is characterized by drug-related overdose deaths primarily attributed to illicit synthetic opioids such as fentanyl3. Methadone, a synthetic opioid created in the 1940s for pain management with a longer half-life compared to other opioid substances, has been used in treating opioid addiction globally for over four decades through methadone maintenance treatment (MMT)4,5. The affordability and easy accessibility of methadone formulations are contributing factors to the rising incidence of opioid poisoning5,6. According to the United Nations Office on Drugs and Crime, Iran is located along one of the world’s major opioid trafficking routes because of its extensive border with Afghanistan and Pakistan. At the same time the widespread implementation of MMT programs has increased the availability of methadone, contributing to a growing number of methadone poisoning cases7,8. Although cardiovascular disease and cancer account for many deaths among patients receiving MMT, methadone overdose remains an important cause of mortality, particularly during treatment initiation or in the presence of concomitant substance use. Therefore, improving the management of methadone overdose remains an important clinical priority in settings where MMT programs are widely implemented9,10.
The latest research reveals that methadone use is the leading cause of poisoning incidents in this country, with most individuals consuming the drug orally in syrup and pill forms5. Methadone overdose results in clinical symptoms such as loss of consciousness, respiratory depression (bradypnea/apnea), cardiovascular problems (hypotension, cardiac arrhythmia, and QT prolongation), nausea, vomiting, seizures, and miosis11,12.
Naloxone, the first competitive antagonist of opioids, was first patented in 1960. Its high binding affinity for the μ-receptor and its capacity to reverse both the central and peripheral effects of opioids resulted in its widespread acceptance as the standard therapy for opioid toxicity13. According to the latest guidelines, the administration of naloxone should be adjusted to maintain a balance between the necessity for treatment and the potential for misuse or adverse events14,15. While any dosage form can effectively reverse an overdose if administered correctly, it is essential to consider various factors. These include the adverse effects linked to different routes of administration, the time taken for the administrator to arrive, the time it takes for naloxone to act, financial considerations, and the possibility of inducing opioid withdrawal along with its accompanying physiological and psychological disturbances, such as acute behavioral changes16,17. Naloxone is available in intravenous (IV), intramuscular (IM), and intranasal (IN) formulations. In many Western countries, intranasal naloxone has been widely implemented in community and prehospital settings as part of take-home overdose programs owing to its ease of administration and favorable safety profile. Nebulized naloxone administered via face mask has also been used in selected emergency medical service settings as a needle-free alternative, although drug delivery may be less predictable compared with injectable routes. Compared with IV administration, non-injectable routes generally have lower bioavailability and a slower onset of action, whereas IV and IM naloxone remain the preferred routes in hospital settings where rapid titration and reliable absorption are required15,18,19.
When dealing with opioid toxicity caused by long-acting opioids or those with high receptor affinity, a continuous infusion of naloxone may be necessary to prevent a return to sedation after initial treatment of acute toxicity14. To address concerns about precipitating acute opioid withdrawal, a titrated intravenous approach is commonly recommended18. However, challenges associated with intravenous naloxone administration have prompted efforts to explore alternative delivery methods. Existing venous damage can interfere with the administration of an antidote20, while individuals who inject drugs also face an elevated risk of transmitting blood-borne infections to healthcare workers through needlestick injuries21. In the prehospital setting, large single doses of naloxone are commonly administered intramuscularly owing to practicality and safety considerations22. In a retrospective observational study by Harris et al.23, the authors demonstrated that an intramuscular dose of naloxone effectively reversed suspected heroin overdose toxicity in most patients. Furthermore, patients treated with intramuscular naloxone were less likely to require repeated intermittent doses or infusion compared with those treated with intravenous naloxone. Taking into account that methadone is used as a maintenance treatment in opioid substitution therapy in opioid-dependent patients owing to its long half-life, this randomized controlled trial aimed to explore the effect of intramuscular naloxone in comparison with intravenous naloxone in opioid-dependent patients with methadone overdose, comparing these two routes with regard to opioid withdrawal symptoms, response rate, and apnea.
Method
Study design and setting
This study was an open-label randomized clinical trial conducted on patients with methadone overdose at a Medical Toxicology Unit in a referral center for poisoning in Tehran, Iran, from March 2022 to March 2023. Written informed consent was obtained from the patient or the next of kin before randomization in all cases. The protocol was approved by the ethics committee of Shahid Beheshti University of Medical Sciences and registered with the Iranian Registry of Clinical Trials (IRCT; Approval code: IRCT20120629010133N6). All research was performed in accordance with the Declaration of Helsinki.
Population
We enrolled patients aged 19–59 years with suspected methadone overdose, based on a history of methadone overdose as the primary drug and clinical manifestations of opioid toxidrome, including miotic pupils and loss of consciousness (with or without respiratory depression, defined as a respiratory rate of less than 10 per minute), who responded (either completely or partially; see below) to bolus naloxone administration before or after ED presentation. We excluded patients who required endotracheal intubation on arrival, those with mixed drug poisoning in which methadone was not the primary toxicant (For instance, patients presenting with QRS widening due to tricyclic antidepressant poisoning who also required Naloxone for Methadone overdose), those with no methadone detected on urinary screening, those with no response to naloxone, or those who did not consent to participate in the study.
Interventions
Patients were randomly assigned to receive either IM or IV naloxone.
In the intravenous injection group, a continuous IV infusion of naloxone, at two-thirds of the initial bolus dose, was initiated and adjusted according to venous blood gas (VBG) results and level of consciousness. In the intramuscular injection group, 0.4 mg IM naloxone was administered if the calculated infusion dose was below 0.2 mg/hr, 0.8 mg IM naloxone for infusion doses between 0.2 and 0.4 mg/hr, 1.2 mg IM naloxone for doses between 0.4 and 0.6 mg/hr, and 1.6 mg IM naloxone for infusion doses exceeding 0.6 mg/hr, administered over a 4-h period.
The allocation sequence was generated in a single session by the principal investigator using a random digit generator website (https://www.random.org). The PI informed the staff of the randomization sequence for one block of 4 participants at a time.
Patients’ conditions were monitored by trained medical staff throughout their hospital stay, including blood gas measurement every 4 h, assessment of withdrawal symptoms using the Clinical Opiate Withdrawal Scale (COWS), electrocardiogram monitoring, presence of apnea (if any), and oxygen saturation measurements. Treatment was continued until mental status improved or respiratory function normalized, using the least amount of antidote necessary.
Primary and secondary outcomes
The primary outcome was the trajectory of COWS scores over the first 72 h following naloxone administration, assessed at 4-h intervals. Group comparisons were performed using repeated-measures analysis. For descriptive purposes, COWS scores were categorized as (a) no withdrawal syndrome when the score was less than 5, (b) mild withdrawal syndrome when the score was between 5–13, (c) moderate when the score was 13–24, (d) moderately severe for scores between 25–36, and (e) severe withdrawal when the score exceeded 3624. COWS scores are presented as median [interquartile range].
The secondary outcome was the need for rescue IV dosing based on the response to naloxone treatment, categorized into two levels25:
-
1.
Complete (full) response: indicated by complete arousal to normal consciousness.
-
2.
Partial (but adequate) response: indicated by an increase in respiratory rate, with oxygen saturation above 90% but with residual sedation.
Secondary outcomes also included blood pH, PaCO2, and oxygen saturation levels measured by pulse oximetry and venous blood gas analysis.
Sample size and data collection
Since no previous studies have directly compared IV and IM naloxone in methadone-poisoned patients, the sample size was calculated based on pilot data from 15 patients. No cases of apnea or severe withdrawal syndrome were observed with intramuscular naloxone, whereas severe withdrawal syndrome occurred in approximately 18% of opioid-dependent patients treated with routine IV naloxone infusion. Severe withdrawal was defined as a Clinical Opioid Withdrawal Scale (COWS) score greater than 3625.
For the current trial, we conservatively assumed a 4% incidence of severe withdrawal in the IM group and 18% in the IV group. Using a two-sided test for comparison of proportions, with α = 0.05, power = 80%, and a 1:1 allocation ratio, the required sample size was calculated as 154 patients (77 per group). To account for potential exclusions or incomplete data, we increased the total sample size to 160 patients (80 per group).
A pre-formatted form was used (by A.J.) to record demographic and clinical variables. The variables evaluated included patient age, gender, prior opioid dependency and duration of use, amount of methadone ingested (if known), decreased level of consciousness (if any) on presentation, naloxone dose (mg) before admission which was given intravenously as per local protocol, development of withdrawal after naloxone administration and its severity as determined by COWS, and laboratory tests including 4-hourly venous blood gas analyses. Need for re-administration of naloxone and apnea after initial doses or during treatment were also recorded. Ward nurses were responsible for administering IV and IM naloxone, measuring vital signs, and recording other events. There was no blinding of naloxone allocation. Most data were collected prospectively; the amount and time of methadone ingestion were determined retrospectively from the patient.
Data management and statistical analysis
Data were transcribed into IBM SPSS version 27.0 (SPSS Inc., Chicago, IL, USA) from the case-record forms for further analysis. Descriptive data were summarized as median [interquartile range]. Fisher’s exact test or the Chi-squared test was used to compare proportions, and the Mann–Whitney U test or Independent-Samples Kruskal–Wallis test was used to compare continuous or categorical variables. P-values less than 0.05 were considered statistically significant.
Results
Of 486 opioid overdose cases during the study period, 53 patients required endotracheal intubation and were excluded from the study, 149 patients had mixed opioid-drug these ob, and 124 patients did not consent to participate in the study; thus, a total of 160 patients presenting to the emergency department with suspected methadone overdose were enrolled in this randomized trial and allocated to either the intramuscular injection group or the intravenous injection group. Table 1 displays the baseline demographic and clinical characteristics of the patients based on their assigned treatment. In the intramuscular group, the median [IQR] age of the participants was 35 [28, 45] years, with 48.6% being men, while in the intravenous group, the median age was 30 [21, 42], with 51.4% being men. The groups were similar in terms of age, sex, duration of drug use, ingested dose of methadone, and pre-hospital naloxone administration (Table 1). The two groups did not differ significantly in response to naloxone (P = 0.705). In the IM group, 50.0% had a known history of opioid dependence, while in the IV group, known opioid dependence was present in 41.3% of patients.
Upon hospital arrival, both groups commonly presented with decreased level of consciousness and apnea as predominant symptoms, with additional symptoms such as cyanosis and respiratory distress detailed in Table 1. As shown in Table 2, treatment with intravenous naloxone resulted in a significantly higher pulse rate indicative of withdrawal symptoms. Supplementary Table 1 shows the details of the 11 elements of the COWS items at different intervals. Figure 1 depicts COWS scores, showing higher withdrawal severity in the IV group. The point-to-point comparison across COWS time intervals showed that the score difference was significant at most time intervals before 48 h (Table 3). The comparison of total COWS scores between the two groups is available in Table 3. Converting the scores to severity categories showed that there were no severe or moderately severe cases in the IM group (Fig. 2). During hospitalization, 38 episodes of apnea were recorded, occurring from almost immediately after intervention up to 24 h thereafter. All cases of apnea were reversed with a single rescue dose of naloxone. The peak time of apnea occurrence was two hours post-intervention in both groups (Fig. 3). There was no difference in IM naloxone doses with respect to the occurrence of apnea or its timing post-intervention. Likewise, no difference in COWS score was found across different doses of IM naloxone at four hours post-intervention (Table 4).
Clinical Opioid Withdrawal Scale in IV (orange) versus IM (blue) post intervention in different time intervals.
Severity of withdrawal symptoms in each group according to COWS severity criteria post intervention in two groups (n = 160).
Frequency of apnea during hospitalization in two groups (n = 160).
Discussion
Several mechanisms may explain overdose in patients receiving MMT. First, methadone has a long and variable half-life, and drug accumulation during induction or dose escalation may increase the risk of respiratory depression, particularly in the first weeks of treatment. Second, concomitant use of other central nervous system depressants (e.g., benzodiazepines, alcohol, or illicit opioids) significantly increases overdose risk. Third, unsupervised or take-home methadone doses may result in misuse, diversion, or unintentional overconsumption. Inadequate monitoring, comorbid medical conditions, and reduced tolerance after treatment interruption may also contribute to overdose risk.
Previous studies have reported that overdose remains one of the leading causes of mortality among individuals receiving MMT, particularly in specific high-risk populations26,27. In Iran, where MMT centers are widely available, methadone-related poisoning has emerged as an important public health concern, partly related to accessibility and take-home dosing practices28.
To minimize acute opioid withdrawal after naloxone administration, many clinicians prefer using small, titrated intravenous (IV) boluses during the initial management of opioid poisoning29. IM naloxone is rarely used in hospital settings as the first-line antidotal treatment. The current study revealed significant differences between the IV and IM groups in terms of COWS score. Patients who received intramuscular injection exhibited lower COWS scores overall, with lower scores for each symptom.
A recent prospective study investigating acute opioid withdrawal after IM injection of 1.6 mg naloxone found that behavioral disturbances were rare and seldom required sedative intervention30. Similar outcomes were observed by Harris et al.21. These findings differ from those of a review of 43 studies on naloxone administration20; however, the high heterogeneity among studies and the lack of systematic methodology in this review should also be considered.
There is a lack of data comparing COWS scores following IV and IM naloxone injection in a hospital setting. Kelly et al.31 reported a higher occurrence of agitation/irritability after naloxone treatment in patients who received IM treatment compared with intranasal treatment. The authors proposed that this may be due to a more rapid response and absorption with the intramuscular dosage form. Interestingly, IM naloxone reaches peak concentration after approximately 5 min but maintains therapeutic levels for up to 4 h. By contrast, IV naloxone produces higher initial concentrations that decline rapidly within 30 to 60 min32. These pharmacokinetic differences suggest a potential ranking of administration routes from highest to lowest risk of withdrawal symptoms as IV, IM, and IN. However, further prospective studies are needed to confirm this relationship. There remains hesitancy in adopting IM naloxone as the primary standard treatment for opioid overdose, with a titrated IV approach often recommended owing to its lower risk of triggering acute opioid withdrawal. In our trial, patients undergoing IM treatment achieved lower scores across all COWS items.
There was no significant difference in the need for rescue naloxone during hospitalization based on the route of naloxone administration. This may suggest that both intramuscular and intravenous routes were equally effective in preventing the recurrence of opioid toxicity following initial naloxone doses.
In cases of opioid toxicity caused by long-acting opioids such as methadone, a continuous infusion of naloxone may be necessary to prevent re-narcosis after initial treatment of acute toxicity14. In Iran’s hospital settings, the IV route is typically used for naloxone administration in patients with drug toxicity who often have altered mental status or are intoxicated with multiple substances, requiring IV access33. Nevertheless, challenges associated with IV administration, including difficulty obtaining IV access and an increased risk of disease transmission, warrant the need for alternative routes of antidote delivery21.
Most studies in this field have focused on the effectiveness of intramuscular (IM) injection in prehospital settings as a first-line treatment owing to its ease of administration. One of the earliest studies comparing IM with IV access was conducted by Sporer et al.34, who aimed to assess the efficacy of opioid overdose reversal treatment in an out-of-hospital setting. They found a similar response rate, over 90%, among patients who received IM naloxone with bag-valve-mask ventilation compared with those who received IV naloxone. However, data on the treatment protocol during hospital stays of admitted patients were not reported.
Furthermore, Harris et al.23 conducted a retrospective study on patients with heroin poisoning, revealing that a single 1.6 mg IM dose of naloxone effectively reversed the toxicity of suspected heroin overdose in the majority of cases, with few patients (10%) requiring a subsequent naloxone infusion, compared with 29% of patients initially administered small titrated IV naloxone. Isoradi et al. suggested that adding 1.6 mg IM naloxone to 0.1 mg titrated intravenous naloxone could prolong effective reversal of respiratory depression, with fewer naloxone doses and infusions given, and no significant difference in the development of withdrawal30. In their RCT, this intervention prolonged effective reversal of respiratory depression, with fewer naloxone doses and infusions given, and no significant difference in patients developing withdrawal35. Considering the different design and setting, and the fact that we targeted long-acting opioids, these results align partially with our study, as both IM and IV approaches demonstrated efficacy in improving patients’ conditions, with neither method proving superior to the other. However, the COWS score was substantially lower with IM injection, without correlation to the administered dose. The discrepancy in outcomes between the two administration routes may be attributed to the low likelihood of recurrence of opioid toxicity following naloxone treatment initiated in the prehospital setting. A study conducted in the Finnish population highlighted that all cases of toxicity recurrence in patients who arrived at the hospital after prehospital naloxone administration occurred within one hour of treatment36. Given that most of our patients received naloxone prior to hospital admission, any true differences between the IM and IV approaches may have been minimized.
Moreover, Kelly et al. found that patients in the IM treatment group were more likely to have more than 10 spontaneous respirations per minute within 8 min compared with intranasal administration28. In our study, there was no significant difference between the IV and IM routes in terms of O2 saturation and blood gas parameters.
Although this study was performed in patients with methadone overdose, the pharmacological mechanism of naloxone suggests that similar findings may be applicable to overdoses involving other full μ-opioid receptor agonists; however, this hypothesis requires confirmation in dedicated clinical studies.
An important strength of this study is that, to our knowledge, it is one of the first randomized controlled trials directly comparing maintenance intramuscular and intravenous naloxone for hospitalized patients with methadone overdose. The randomized design, prospective collection of clinical outcomes, and standardized assessment of opioid withdrawal using the COWS enhance the internal validity of the findings and provide clinically relevant evidence regarding an alternative route of naloxone administration.
Limitations
There are several limitations that should be considered. This study was conducted at a single center, which may limit the generalizability of the findings to all patients. While naloxone dosage in both groups was titrated based on the initial dose and the patient’s condition, it is possible that an inadequate naloxone dosage could have led to a failure to achieve a complete response. Additionally, the majority of our study population had concomitant use of other depressants and illicit drugs, as confirmed by laboratory tests, which is common among substance users. However, this could have potentially confounded the true response to naloxone treatment if the intoxication was not solely due to methadone. Having serum methadone levels available could have increased the validity of our study, but such tests were unavailable at our center. Although all enrolled patients fulfilled predefined clinical criteria for suspected methadone overdose, including a compatible history, clinical features of opioid toxidrome, and response to naloxone, confirmatory quantitative toxicological testing was not available. Therefore, the findings should be interpreted primarily in the context of clinically diagnosed methadone overdose rather than toxicologically confirmed methadone poisoning. Some degree of exposure misclassification cannot be completely excluded, particularly in patients with concomitant substance use, and this may have influenced the observed treatment effects. The lack of confirmatory advanced laboratory measurements to confirm the exact drugs involved, coupled with the potential unreliability of patients’ self-reported history of drug use, may have caused patients who received intramuscular (IM) treatment to appear to be in better condition initially, potentially overstating the effectiveness or safety of this route of administration. Furthermore, owing to the difference in drug administration route, blinding of patients and nurses (care providers) to the treatment plan was not feasible. Additionally, since many items in the COWS score depend on observer evaluation, the investigators would have been prone to observer bias, which could have led to overestimation of the clinical findings in our study.
Conclusion
In conclusion, our findings underscore the importance of balancing the efficacy of the treatment approach, including the route of administration, with the potential adverse events associated with that choice when considering naloxone treatment. Among patients with clinically diagnosed methadone overdose, IM naloxone may represent a reasonable alternative to IV infusion, offering possible advantages including ease of administration, lower COWS scores, and a lower risk of blood-borne pathogen transmission. However, these findings should be interpreted within the context of clinically diagnosed methadone overdose, because confirmatory toxicological testing was unavailable.
In this randomized controlled trial, both IV and IM administration of naloxone demonstrated comparable efficacy in reversing methadone overdose, with no significant difference observed in the need for rescue doses during hospitalization. Given the lower COWS scores observed, IM naloxone may be considered in selected clinical settings for methadone overdose and potentially other long-acting opioid overdoses.
Data availability
All collected and analyzed data can be made available by the corresponding author upon request.
References
Scholl, L. Drug and opioid-involved overdose deaths—United States, 2013–2017. MMWR Morb. Mortal. Wkly. Rep. 67, 1419–1427 (2019).
Centers for Disease Control and Prevention. Understanding the Opioid Overdose Epidemic. Available at: https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html. Accessed July 2026.
Hedegaard, H., Miniño, A. M. & Warner, M. Urban-rural differences in drug overdose death rates, by sex, age, and type of drugs involved, 2017. NCHS Data Brief. 345, 1–8 (2019).
Lugo, R. A., Satterfield, K. L. & Kern, S. E. Pharmacokinetics of methadone. J. Pain Palliat. Care Pharmacother. 19(4), 13–24 (2005).
Ramezanzadeh, H. et al. Epidemiological aspects of opioid poisoning in Northern Iran: A registry-based clinical study. Health Serv Insights. 17, 11786329241232300 (2024).
Ostling, P. S. et al. America’s opioid epidemic: A comprehensive review and look into the rising crisis. Curr. Pain Headache Rep. 22, 1–7 (2018).
Vanani, A. R., Rahmani, A. H. & Payam, S. P. An investigation of the clinical signs, and frequency of street drug poisoning in patients referred to Razi Hospital of Ahvaz city, 2008–2013. Asia Pac. J. Med. Toxicol. 85(2), 56–60 (2019).
Hassanian-Moghaddam, H. et al. Risk factors for mortality and endotracheal intubation after methadone intoxication. Basic Clin. Pharmacol. Toxicol. 118(3), 231–237 (2016).
Rosca, P. et al. Mortality and causes of death among users of methadone maintenance treatment in Israel, 1999-2008. Drug Alcohol Depend. 125(1–2), 160–163 (1999).
Shadnia, S., Rahimi, M., Hassanian-Moghaddam, H., Soltaninejad, K. & Noroozi, A. Methadone toxicity: Comparing tablet and syrup formulations during a decade in an academic poison center of Iran. Clin. Toxicol. (Phila). 51(8), 777–782 (2013).
Glaizal, M. et al. Suicidal poisonings with methadone in France: Results of a two year national survey by the Toxicovigilance Network. Clin. Toxicol. 50(9), 841–846 (2012).
Aghabiklooei, A., Shadnia, S., Hassanian-Moghaddam, H. & Zamani, N. Acute respiratory distress syndrome caused by methadone syrup. Arch. Ind. Hyg. Toxicol. 64(3), 439–443 (2013).
Van Dorp, E. L., Yassen, A. & Dahan, A. Naloxone treatment in opioid addiction: The risks and benefits. Expert Opin. Drug Saf. 6(2), 125–132 (2007).
Dadpour, B., Vahabzadeh, M. & Mostafazadeh, B. Comparison of the efficacy of an infusion pump or standard IV push injection to deliver naloxone in treatment of opioid toxicity. Acute Crit. Care 35(1), 38 (2020).
Saari, T. I., Strang, J. & Dale, O. Clinical pharmacokinetics and pharmacodynamics of naloxone. Clin. Pharmacokinet. 63(4), 397–422 (2024).
Weaver, L., Palombi, L. & Bastianelli, K. M. Naloxone administration for opioid overdose reversal in the prehospital setting: Implications for pharmacists. J. Pharm. Pract. 31(1), 91–98 (2018).
Kim, H. K. & Nelson, L. S. Reducing the harm of opioid overdose with the safe use of naloxone: A pharmacologic review. Expert Opin. Drug Saf. 14(7), 1137–1146 (2015).
Carroll, J. J., Green, T. C. & Noonan, R. K. Evidence-Based Strategies for Preventing Opioid Overdose: What’s Working in the United States (National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 2018).
Weber, J. M., Tataris, K. L., Hoffman, J. D., Aks, S. E. & Mycyk, M. B. Can nebulized naloxone be used safely and effectively by emergency medical services for suspected opioid overdose?. Prehosp. Emerg. Care 16(2), 289–292 (2012).
Fiddes, R., Khattab, M., Dakka, M. A. & Al-Khaffaf, H. Patterns and management of vascular injuries in intravenous drug users: A literature review. Surgeon 8(6), 353–361 (2010).
Dore, G. J. & Thomas, D. L. Management and treatment of injection drug users with hepatitis C virus infection and hepatitis C virus/human immunodeficiency virus coinfection. Semin. Liver Dis. 25(Suppl 1), 18–32 (2005).
Rzasa Lynn, R. & Galinkin, J. Naloxone dosage for opioid reversal: Current evidence and clinical implications. Ther. Adv. Drug Saf. 9(1), 63–88 (2018).
Harris, K. et al. One single large intramuscular dose of naloxone is effective and safe in suspected heroin poisoning. Emerg. Med. Australas. 32(1), 88–92 (2020).
Wesson, D. R. & Ling, W. The clinical opiate withdrawal scale (COWS). J. Psychoactive Drugs 35(2), 253–259 (2003).
Zamani, N., Buckley, N. A. & Hassanian-Moghaddam, H. Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: A prospective randomized trial. Crit. Care 24(1), 44 (2020).
Nazmin, F. et al. Systematic review on mortality in the elderly on methadone maintenance treatment. Cureus. 16(9), e68910 (2024).
Russolillo, A., Moniruzzaman, A. & Somers, J. M. Methadone maintenance treatment and mortality in people with criminal convictions: A population-based retrospective cohort study from Canada. PLoS Med. 15(7), e1002625 (2018).
Rostam-Abadi, Y. et al. Public health risks associated with methadone in Iran: A systematic review and meta-analysis. Int. J. Drug Policy 100, 103529 (2022).
Connors, N. J. & Nelson, L. S. The evolution of recommended naloxone dosing for opioid overdose by medical specialty. J. Med. Toxicol. 12(3), 276–281 (2016).
Isoardi, K. Z., Parker, L., Harris, K., Rashford, S. & Isbister, G. K. Acute opioid withdrawal following intramuscular administration of naloxone 1.6 mg: A prospective out-of-hospital series. Ann. Emerg. Med. 80(2), 120–126 (2022).
Kelly, A. M. et al. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med. J. Aust. 182(1), 24–27 (2005).
Dowling, J., Isbister, G. K., Kirkpatrick, C. M., Naidoo, D. & Graudins, A. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther. Drug Monit. 30(4), 490–496 (2008).
Sabzghabaee, A. M., Eizadi-Mood, N., Yaraghi, A. & Zandifar, S. Naloxone therapy in opioid overdose patients: Intranasal or intravenous? A randomized clinical trial. Arch. Med. Sci. 10(2), 309–314 (2014).
Sporer, K. A., Firestone, J. & Isaacs, S. M. Out-of-hospital treatment of opioid overdoses in an urban setting. Acad. Emerg. Med. 3(7), 660–667 (1996).
Isoardi, K. Z., Harris, K., Currey, E., Buckley, N. A. & Isbister, G. K. Effectiveness of intramuscular naloxone 1,600 μg in addition to titrated intravenous naloxone 100 μg for opioid poisoning: A randomised controlled trial. Clin. Toxicol. 62(10), 643–650 (2024).
Willman, M. W., Liss, D. B., Schwarz, E. S. & Mullins, M. E. Do heroin overdose patients require observation after receiving naloxone?. Clin. Toxicol. 55(2), 81–87 (2017).
Acknowledgements
We acknowledge all colleagues who agreed to include their patients and in particular all nurses who take care of patients in this RCT.
Funding
This study was supported by a grant approved by Shahid Beheshti University of Medical Sciences (Project ID: 32908).
Author information
Authors and Affiliations
Department of Emergency Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Ali Jangjou
Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Ali-Asghar Kolahi & Hossein Hassanian-Moghaddam
Department of Community Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Mahbobeh Taheri
School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Amir Hossein Hassani
School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Niloofar Deravi
European Union Drugs Agency, Lisbon, Portugal
Rebecca McDonald
Clinical Pharmacology, Sydney Pharmacy School, University of Sydney, Sydney, Australia
Nicholas Buckley
Next Step Drug and Alcohol Services, Royal Perth Bentley Group, Perth, Australia
Hossein Hassanian-Moghaddam
National Drug Research Institute, Curtin University, Perth, Australia
Hossein Hassanian-Moghaddam
Authors
- Ali Jangjou
- Ali-Asghar Kolahi
- Mahbobeh Taheri
- Amir Hossein Hassani
- Niloofar Deravi
- Rebecca McDonald
- Nicholas Buckley
- Hossein Hassanian-Moghaddam
Contributions
NB, RM, AK and HHM conceived and designed the study. AJ and MT acquired the data and performed the first round of analysis. ND drafted the manuscript. HHM and AHH re-performed the analysis and finalised the manuscript. The final version of the manuscript was reviewed and approved by all authors.
Corresponding author
Correspondence to Hossein Hassanian-Moghaddam.
Ethics declarations
Competing interests
The authors declare that no competing interests.
Ethics approval and consent to participate
The study was approved by local ethics committee in Shahid Beheshti University of Medical Sciences as well as registered in the Iranian Registry of Clinical Trials (Trial ID: 32908; Approval code: IR.SBMU.RETECH.REC.1401.580) in December 2022. Consent was taken from patients’ next of kin before inclusion in all cases.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Jangjou, A., Kolahi, AA., Taheri, M. et al. Intramuscular versus intravenous naloxone for the reversal of methadone overdose in hospitalized patients: a randomized clinical trial. Sci Rep 16, 38490 (2026). https://doi.org/10.1038/s41598-026-64972-0
Received: 01 October 2025
Accepted: 28 July 2026
Published: 18 November 2026
Version of record: 18 November 2026
DOI: https://doi.org/10.1038/s41598-026-64972-0
来源:Nature 健康护理主题 · nature.com